119. the Effects of Lentiviral Gene Therapy with Bone Morphogenetic Protein-2-Producing Bone Marrow Cells on Spinal Fusion in Rats

Masashi Miyazaki,Osamu Sugiyama,Benjamin Tow,Jun Zou,Yuichiro Morishita,Wei Feng,Antonia Passarelli di Napoli,Chananit Sintuu,Jay R. Lieberman,Jeffrey C. Wang

DOI: https://doi.org/10.1016/j.spinee.2007.07.141

IF: 4.297

2007-01-01

The Spine Journal

Abstract:BACKGROUND CONTEXT: Spinal arthrodesis is a commonly performed spinal procedure and autograft remains the standard for achieving spinal fusion. However, its procurement is associated with significant morbidity, and pseudoarthrosis rates exceeding 40% have been reported. Nonunion frequently leads to an unsatisfactory resolution of clinical symptoms and usually results in high medical costs and morbidity as well as the need for additional surgeries. These problems have led surgeons to search for alternative solutions to stimulate bone formation. rhBMPs have also been used successfully in clinical trials. However, large doses of BMPs were required to induce adequate bone repair. The development of a regional gene therapy may be a more efficient method to deliver proteins to a specic anatomic site. Furthermore, adeno-BMP-2-producing rat bone marrow-derived cells have been used successfully to induce posterior spinal fusion. Recently, lentiviral vectors based on human immunodeficiency virus have been developed for gene therapy. Lentiviruses are capable of insertion into the host genome, ensuring a prolonged gene expression. However, safety issues are a major concern when adopting these vectors for clinical use.